Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29196085 | 0.84 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1MAPTPTPRCGLA | |
| SCHEMBL8088891 | 0.83 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1MAPTPTPRCMAPK1 | |
| SCHEMBL6667569 | 0.83 | DRD1 (0.44) | ADRB2L3MBTL1HTR7RAB9ATP53 | |
| SCHEMBL215578 | 0.82 | ADORA3 (0.43) | ALDH1A1ADORA3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL7962688 | 0.82 | KDM4E (0.43) | ADRB2ALDH1A1HTR7SMN1; SMN2RAB9A | |
| SCHEMBL27270775 | 0.81 | LTA4H (0.54) | ALDH1A1MAPTSMN1; SMN2RAB9ATP53 | |
| SCHEMBL730864 | 0.81 | CYP1A1 (0.45) | ALDH1A1L3MBTL1ADORA1ADORA2AHTR7 | |
| SCHEMBL693820 | 0.80 | CA12 (0.39) | ADRB2ALDH1A1L3MBTL1HTR7MAPT | |
| SCHEMBL444326 | 0.79 | PTPRC (0.51) | ADRB2ALDH1A1L3MBTL1HTR7MAPT | |
| SCHEMBL27610647 | 0.78 | PTPRC (0.48) | ADRB2ALDH1A1L3MBTL1HTR7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| US-6399653-B1 | METABOLISM DIORDERS; CARDIOVASCULAR DISORDERS; NERVOUS SYSTEM DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-06-04 | — | — | US | disclosed |
| US-4267117-A | INTERMEDIATES FOR 1A-HYDROXYLATED CALCIFEROLS | THE UPJOHN COMPANY (US) | 1981-05-12 | — | — | US | disclosed |
| US-4206131-A | 1A-HYDROXYLATED CALCIFEROLS | THE UPJOHN COMPANY (US) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | ADRB2 25/4885ALDH1A1 204/4885L3MBTL1 3966/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | ADRB2 29/4885ALDH1A1 256/4885L3MBTL1 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.